AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$MCK

Rodgers Thomas L sold $604K of MCK

Rodgers Thomas L (EVP, Chief Strategy & BDO) sold 822 shares of MCKESSON CORP (MCK) at an average of $735.30 ($735.27–$735.50, $0.60M total) across 2 trades over 2026-06-01 to 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rodgers Thomas L
Published Jun 3, 2026, 3:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MCK
Bearish
medium confidence
Mentioned
$MCK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKBearishLow
01

Why it matters

The disclosed sale may trigger short‑term selling pressure, but the pre‑arranged nature tempers the signal.

02

Market read

A modest insider sale by a senior executive, reported via a primary SEC filing, offers limited trading relevance.

03

What to watch

The 10b5-1 plan indicates the sale was pre‑scheduled, reducing the informational weight of the transaction.

Relevance 4/10Novelty 4/10Timing: post-market filing

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$MCKBearishMedium confidence
Context

EVP Rodgers Thomas L sold 822 shares for $604,420 via a 10b5-1 plan, reducing his stake to 2,268 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

Insider sales, especially by a senior executive, often lead to short-term sell pressure despite the modest size.

Market effects

Sector

Minimal impact on the healthcare distribution sector; only a micro‑level signal.

Regional

U.S. market only; no broader regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing under a pre‑arranged plan, not a negative signal.

Key entities

  • Executive
    Rodgers Thomas L

    EVP, Chief Strategy & BDO at McKesson Corp.

  • Company
    McKesson Corp

    U.S. healthcare services and information technology company.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MCK insider trading history →

Related articles

OCT 10
$OPCHHighAI 9/10

Option Care Health Sold for $5.8B in CD&R-McKesson Deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson (MCK) for $5.8B, or $32.05 per share, a 37% premium. The deal, expected to close in 2027, values the company at $5.8B. Option Care Health will operate independently post-acquisition. The company reported $5.6B in 2025 revenue and $207.6M in net income, with modest growth in 2026. The acquisition aligns with McKesson's strategy to expand access to innovative therapies.

hoodline.com2 min
OCT 9
$MCKHighAI 9/10

McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?

McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.

finance.yahoo.com2 min
OCT 8
$MCKHighAI 9/10

McKesson & CD&R Acquire Leading US Home-Infusion Platform

McKesson and private equity firm CD&R will acquire Option Care Health, a US home-infusion care provider, for $5.8bn. CD&R will take a majority stake, while McKesson invests $1.4bn for a minority stake. The deal values Option Care Health at $32.05 per share and is expected to close in H1 2027. McKesson aims to leverage the acquisition to expand its specialty care offerings.

healthcare-digital.com3 min
OCT 7
$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

finance.yahoo.com2 min
OCT 7
$MCKHighAI 9/10

McKesson Plans $1.4 Billion Stake in $5.8 Billion Option Care Buyout

McKesson plans a $1.4B investment for a 49% stake in Option Care Health, part of a $5.8B buyout by Clayton, Dubilier & Rice. Shareholders will receive $32.05 per share. The deal, pending approvals, is expected to close in early 2027. Option Care shares rose 32.7% on the news. McKesson's Q1 revenue grew 8% to $105.4B, with net income down 22% to $614M.

finchannel.com2 min